Kurma invests £7.7 million in B cell-selective antibody spin-out from CRT
This article was originally published in Scrip
Kurma Life Sciences Partners has invested £1.1 million seed financing with the commitment of a further £6.6 million to start-up BliNK Therapeutics, a spin-out company from Cancer Research Technology. BLiNK has a novel antibody platform that is designed to explore the huge spectrum of antibody variability that conventional methods cannot fathom.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.